Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
631 articles by Ben Fidler
-
Pfizer hemophilia gene therapy arrives in US to uncertain future
April 26, 2024 -
FDA rejects Abeona cell therapy, asks for more manufacturing data
April 23, 2024 -
Pharmas form joint venture to jumpstart Japanese drug research
April 22, 2024 -
Roche wins FDA OK for Alecensa in early lung cancer
April 19, 2024 -
Vertex begins bid for US approval of non-opioid painkiller
April 18, 2024 -
Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
April 18, 2024 -
Contineum prices biotech’s latest IPO, raising $110M for neuroinflammatory drugs
April 4, 2024 -
Gritstone shares fall on shaky study results for colorectal cancer vaccine
April 2, 2024 -
AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout
April 1, 2024 -
Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup
March 28, 2024 -
FDA clears first-of-its-kind Duchenne drug for broad use
March 22, 2024 -
Medicare to cover Novo’s obesity drug for some patients
March 22, 2024 -
Capstan heats up ‘in vivo’ cell therapy chase with $175M fundraise
March 20, 2024 -
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
March 19, 2024 -
Contineum, a startup born from a Roche buyout, files for IPO
March 17, 2024 -
Madrigal, FDA approval in hand, outlines plan to sell MASH drug
March 15, 2024 -
Madrigal wins FDA approval of first drug for MASH
March 14, 2024 -
J&J, Novo support Asgard’s push to make ‘in vivo’ cell therapies
March 14, 2024 -
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
March 12, 2024 -
Biotech stock fundings headed for best quarter in 3 years, Jefferies says
March 11, 2024 -
FDA clears use of Novo’s obesity drug to protect heart health
March 8, 2024 -
Biotech IPOs heated up to start 2024. Will the surge last?
March 5, 2024 -
Akero strengthens MASH drug’s case with new study data
March 4, 2024 -
Bayer pays $310M to buy into BridgeBio heart drug
March 4, 2024 -
Gritstone to lay off 40% of workforce after costly study delay
March 1, 2024